Keywords: Daiichi Sankyo, Biomarkers, Cancer drug development, Personalized medicines
Daiichi Sankyo research exec points out “a lot of hype” around biomarkers
Article | 17 October 2011
Robert Beckman, executive director, clinical development oncology at Japanese drug major Daiichi Sankyo (TYO: 4568), has spoken openly about his work ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
